FOLD — Amicus Therapeutics, Inc.

Amicus Therapeutics (FOLD) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $169.1 million, a 19% increase year-over-year (17% at constant exchange rates).
• Galafold Revenue: $138.3 million, up 15% reported and 12% at constant exchange rates; 13% year-over-year patient growth.
• Pombiliti and Opfolda Revenue: $30.7 million, up 45% reported and 42% at constant exchange rates; year-to-date growth of 61%.
• GAAP Net Income: $17.3 million ($0.06 per share), compared to a net loss of $6.7 million in Q3 2024.
• Non-GAAP Net Income: $54.2 million ($0.18 per share), up from $30.8 million in Q3 2024.
• Cash Position: $263.8 million as of September 30, 2025, an increase of $32.8 million from the previous quarter.

2. Strategic Updates and Business Highlights

• Product Growth: Strong demand for Galafold, Pombiliti, and Opfolda, with record new patient starts and high market shares (69% for Galafold).
• Scientific Evidence: New data presented at ICIEM supports the efficacy of Pombiliti and Opfolda, enhancing their market positioning.
• DMX-200 Development: Advanced to late-stage Phase III for FSGS, with over 90% enrollment in the ACTION3 study.
• Market Expansion: Successful reimbursement agreements in new countries, including Japan, Belgium, Ireland, and Luxembourg.

3. Forward Guidance and Outlook

• 2025 Revenue Growth Guidance: Total revenue growth of 15% to 22%, with Galafold expected to grow 10% to 15% and Pombiliti and Opfolda projected to grow 50% to 65% at constant exchange rates.
• GAAP Profitability: Expected to continue in the second half of 2025, with a gross margin anticipated in the mid-80s percentage range.

4. Bad News, Challenges, or Points of Concern

• Cost of Goods Sold: Increased to 12% of net sales from 9% year-over-year, indicating rising production costs.
• Operating Expenses: GAAP operating expenses rose to $115.3 million, an 8% increase from Q3 2024, which may pressure future profitability.
• Competitive Pressures: Ongoing competition in the Pompe disease treatment market, with physicians increasingly evaluating multiple therapies.

5. Notable Q&A Insights

• Market Dynamics: Strong patient demand in the U.S. and globally, with improvements in time to reimbursement and adherence rates noted.
• Label Expansion: Discussions around expanding the label for Pombiliti and Opfolda to include pediatric patients, with expected submissions in mid-2026.
• Real-World Evidence: Growing importance of real-world data in influencing physician prescribing patterns, with a focus on long-term treatment durability.
• Market Share Aspirations: Confidence expressed in achieving over 50% market share for Pombiliti and Opfolda in the long term, aiming for $1 billion in peak sales.

Overall, Amicus Therapeutics reported a strong quarter with significant revenue growth and positive net income, while also highlighting strategic initiatives and future growth potential amidst competitive pressures and rising operational costs.